TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 15, 2022 (the “Meeting”). There were 71 shareholders represented in person or by … [Read more…]
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board … [Read more…]
IRVING, Texas–(BUSINESS WIRE)–Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022. The other financial results reported in the original press release, revenue and adjusted EBITDA, … [Read more…]
Upfront $120 million tranche used to finance the full settlement of existing convertible notes held by Deerfield Management Company Deerfield Management Company to take equity as part of the settlement of existing convertible notes Owl Rock to make $6.25 million equity investment Seven-year term loan matures in 2029 and Company maintains cash runway into early … [Read more…]
EsoGuard test volume increased 60% for quarter and over 300% annually CLIA-Certified LucidDx Labs fully operational and billing as an independent entity Conference call to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–$LUCD #investing—Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed … [Read more…]
CARLSBAD, Calif.–(BUSINESS WIRE)–$RMED #Ra_Medical—Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) reports financial results for the three and six months ended June 30, 2022 and provides a business update. “We are continuing to pursue a potential merger with a privately held company, Catheter Precision, Inc., (“Catheter Precision”) which would give our … [Read more…]
AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (“Babylon” or the “Company”), one of the world’s fastest-growing digital healthcare companies, today announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The Company is actively working with the staff of the NYSE to resume trading as … [Read more…]
265% growth in unit sales through direct-to-consumer channels, 97% overall revenue growth vs. Q2 2021 SAN FRANCISCO–(BUSINESS WIRE)–$TIVC #healthcare—Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended June 30, 2022. Jennifer Ernst, CEO of Tivic Health … [Read more…]
BOSTON–(BUSINESS WIRE)–Fish & Richardson secured a significant victory for Exela Pharma Sciences, LLC, the maker of ELCYS®, in patent infringement litigation against Eton Pharmaceuticals, Inc., over its intent to produce a generic version of Exela’s patented ELCYS® product. ELCYS® is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to … [Read more…]
SALT LAKE CITY–(BUSINESS WIRE)–#nasal–Xlear has filed an Amended Answer in response to the U.S. Government’s lawsuit against the company. According to Nathan Jones, Xlear’s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of … [Read more…]
